Nonmyeloablative (NMA) transplants depend largely or solely on graft-versus-tumor effects rather than high-dose therapy to eliminate malignant cells. 1 They seem to be associated with an immunobiology that differs from that of conventional myeloablative hematopoietic stem cell transplantation (HSCT), giving rise to unusual graft-versus-host disease (GVHD) manifestations. 2 The clinical pattern of skin, mouth, liver and ophthalmic involvement in chronic GVHD is well recognized. Progressive weight loss and anorexia are also reported. 3 We describe two cases of vascular leak syndrome (VLS) and serositis as the sole clinical manifestations of chronic GVHD after NMA transplantation.
The first patient is a 48 year old female with an IgG l multiple myeloma received melphalan 200 mg/m 2 followed by an autologous peripheral blood stem cell transplantation (APBSCT) in 2002. The echocardiogram and pulmonary function tests performed pre-transplant were normal. A relapse was followed by an allogeneic NMA HSCT from her HLA-matched sister in 2003. She received fludarabine 30 mg/m 2 for three days followed by low dose TBI (2 Gy), and, cyclosporine (CSA) with mycophenolate mofetil (MMF) as GVHD prophylaxis.
2 By day þ 84, complete donor chimerism was achieved. At day þ 180, she was in minimal residual disease. On day þ 195, she complained of dyspnea and swelling of the lower extremities. Examination revealed mild anasarca with periorbital, pre-sacral and leg edema with a 5 kg weight gain. Blood counts and serum biochemistry were normal except for a moderate eosinophilia. Chest X-ray revealed bilateral pleural effusions, with a normal heart size. An echocardiogram showed a large (27 Â 17 mm) circumferential pericardial effusion with significant hemodynamic compromise consistent with tamponade ( Figure 1 ). Two liters of pericardial fluid (exudate) were drained. The WBC count on the fluid was 162.4 Â 10 9 /L with 95% neutrophils and 5% eosinophils. Tests for legionella, acid fast bacilli, fungus and mycobacteria, viral inclusions, amyloidosis and malignancy were negative. A pericardial biopsy showed a moderate polyclonal perivascular lymphoplasmacytic infiltrate. Blood cultures were negative as was serology for trichinella, helminth eggs and larvae. Anti-nuclear antibodies and complement levels were normal.
The patient was started on prednisone, 1 mg/kg for 4 months, which was then slowly tapered. Serial echocardiograms performed posttreatment were normal (Figure 2 ). After 10 months of therapy, she is asymptomatic. Serum and urine immunofixation are negative. One month later, she presented with dyspnea, chest pain and facial edema. Examination revealed anasarca and a 13 kg weight gain. She had no signs of cGVHD. A chest X-ray revealed an enlarged heart without pleural effusions. An echocardiogram showed a moderate circumferential pericardial effusion without evidence of tamponade.
Serum and urine immunofixation were negative, as were antinuclear and rheumatoid factor antibody titers. Prednisone and tacrolimus induced a rapid response with complete normalization of the echocardiogram and return to baseline weight within 6 weeks of therapy. After five months of therapy, she is asymptomatic.
Both of these patients treated with HLA matched related NMA transplants presented with a VLS and serositis (one with cardiac tamponade) as the sole manifestation of cGVHD. This clinical picture of de novo or quiescent cGVHD is highly unusual in the setting of conventional myeloablative HSCT 3 and closely mimics endothelial cell damage induced by cytokines such as IL-2 secreted by cytotoxic lymphocytes. 4 Silberstein et al recently reported a case of cGVHD with polyserositis, a large pericardial effusion and constrictive pericarditis in the setting of a NMA transplant and subsequent donor lymphocyte infusion. 5 It is tempting to suggest that the distinct immunobiology of NMA transplants could lead to unusual clinical manifestations of cGVHD.
First, the kinetics of engraftment is very different between NMA and conventional transplants. In the myeloablative setting, myeloid, NK, B, and T cells present complete donor chimerism by day þ 21. 6 In the NMA setting, residual recipient immunity is not fully ablated and donor alloreactive T cells engraft slowly over time. 7 These cells are necessary to eradicate host antigen presenting cells (APC) which are key initiators of GVHD. 8 Persisting host APC in the skin or any other host tissues could favor a continued activation of donor alloreactive T cells and cytokine secretion. 9 Secondly, mixed B cell chimerism could lead to host B-cell hyperactivation with increasing autoreactive host B cells. The P-F1 mouse model of cGVHD may be relevant to the pattern of cGVHD observed in human hosts following NMA transplantation and prolonged persistence of host B cells. 10 This cGVHD is largely mediated by auto-antibodies produced by host B cells that are activated by donor CD4 helper T cells. Finally, radiation/chemotherapy induced tissue damage associated with myeloablative conditioning regimens is significantly decreased in NMA transplants. Consequently, the classical early cytokine storm associated with a Th1 secretory cytokine profile is likely to be less intense. It could also occur at a later stage posttransplant. Both scenarios could lead to a modified cytokine secretory profile and promote cGVHD with unusual clinical manifestations. We suggest that any atypical symptom appearing in the context of NMA transplantation should be thoroughly investigated, with biopsies if necessary, in order to identify and characterize unusual cGVHD presentation and improve therapy. 
